The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas: An analysis of 91 cases

Archives of Pathology and Laboratory Medicine

Volumn 125, Issue 7, 2001, Pages 892-898

  Korshunov, A ^a   Golanov, A ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN P21; PROTEIN P27;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; PROGNOSIS;

ADULT; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0034935339     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Clinicopathologic correlations in the oligodendroglioma
2. Cerebral oligodendroglioma: Prognostic factors and life history
3. Oligodendrogliomas, part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases
4. Oligodendrogliomas, part II: A new grading system based on morphological and imaging criteria
5. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases
6. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
7. Oligodendroglioma: The Rotterdam-Dijkzigt experience
8. Oligodendroglioma: A comparison of two grading systems
9. Oligodendroglioma: Histologic evaluation and prognosis
10. Evaluation of malignant features in oligodendroglial tumors
11. The prognostic role of vessel productive changes and vessel density in oligodendroglioma
12. Prognostic factors in oligodendrogliomas
13. Oligodendrogliomas: The Mayo Clinic experience
14. Grading of oligodendrogliomas
15. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas
16. p27/Kip1 expression in oligodendrogliomas and its possible prognostic role
17. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas
18. Prognostic relevance of TP53 mutation, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas
19. CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue
20. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
21. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value
22. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma: An analysis of 91 cases
23. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
24. Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor
25. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas
26. p53 immunoreactivity in oligodendrogliomas
27. Clinico-pathological study of forty-four histologically pure supratentorial oligodendrogliomas
28. Evaluation of cell proliferation, epidermal growth factor receptor and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendrogliomas
29. Vascular endothelial growth factor expression in oligodendrogliomas: A correlative study with Saint-Anne malignancy grade, growth fraction and patient survival
30. Proliferation and cell death in oligodendrogliomas
31. Cell-cycle regulators: Mechanisms and their role in aetiology, prognosis and treatment of cancer
32. p27Kip1: Multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
33. Proteasome-dependent degradation of p27/Kip1 gliomas
34. Ki-S1, a novel proliferative marker: Flow cytometric assessment of staining in human breast carcinoma cells
35. Prognostic value of tumour-associated antigens immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases
36. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival
37. Immunohistochemical staining of DNA topoisomerase II a in human gliomas
38. Immunohistochemical markers for intracranial ependymoma recurrence: An analysis of 88 cases
39. Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas
40. Increased levels of p21 (WAF1/Cip1) in human brain tumors
41. Immunohistochemica] analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis
42. Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy
43. Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas: Correlation with proliferation markers, p53 expression and survival
44. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression
45. p27Kip1 expression by contact inhibition as a prognostic index of human glioma
46. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma
47. Anomalous p27Kip1 expression in a subset of malignant gliomas
48. p27/Kip1 expression in human astrocytic gliomas
49. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing in oligodendrocyte differentiation
50. Ectopic expression of p27Kip1 in oligodendrocyte progenitor cells results in cell-cycle growth arrest
51. High level expression of p27Kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers
52. Multidrug sensitivity of phenotype of human lung cancer cells associated with topoisomerase II expression
53. Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines